Skip to main content

Table 1 Patient’s characteristics

From: Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

 

FOLFIRI3-bevacizumab

(n = 61)

Demographic or clinical characteristics

No. of patients

%

Male

35

57

Age, years

  

  Median

63.6

 

  Range

38-81

 

ECOG performance status

  

  0

25

41

  1

32

52

  2

4

7

Primary tumor type

  

  Colon

38

62

  Rectal

23

38

No. of sites involved by metastases

  

  1

35

57

  2

19

31

  > = 3

7

12

Site of metastatic disease

  

  Liver only

25

41

  Liver + other

20

33

  Other only

16

26

Prior adjuvant chemotherapy

  

  All

18

30

  Oxaliplatin-based

15

25

  < 12 months

8

13

Synchronous tumors

  

  Yes

39

64

  No

22

36